Last reviewed · How we verify
Droxidopa capsules
At a glance
| Generic name | Droxidopa capsules |
|---|---|
| Also known as | Northera, L-threo-3,4-dihydroxyphenylserine |
| Sponsor | H. Lundbeck A/S |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase I/II Study of NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease. (PHASE1, PHASE2)
- NORTHERA (DROXIDOPA) for Dysautonomia in Adult Survivors of Menkes Disease and Occipital Horn Syndrome (PHASE1, PHASE2)
- Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury (PHASE2)
- Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension (PHASE4)
- Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism (PHASE2)
- Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease (PHASE2)
- Long Term Treatment With L-DOPS
- A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Droxidopa capsules CI brief — competitive landscape report
- Droxidopa capsules updates RSS · CI watch RSS
- H. Lundbeck A/S portfolio CI